Drug Profile
Research programme : biosimilars - Huaota Biopharmaceuticals
Alternative Names: HOT-1020Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Huaota Biopharmaceuticals
- Class Antineoplastics; Antipsoriatics; Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Psoriasis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China
- 28 Feb 2022 No recent reports of development identified for preclinical development in Solid-tumours in China
- 28 Feb 2022 No recent reports of development identified for research development in Lymphoma in China